In this episode, menopausal hormone therapy is not associated with breast cancer recurrence and mortality; pandemic-related screening declines may result in ‘increased avoidable cancer deaths’; data on pertuzumab regimen in early breast cancer; and more.
Read the full coverage here:
Menopausal hormone therapy not associated with breast cancer recurrence, mortality
Screening declines after pandemic onset may result in ‘increased avoidable cancer deaths’
Updated data show long-term benefit with pertuzumab regimen in early breast cancer
Medical financial hardship linked to increased mortality risk among cancer survivors
FDA grants priority review to Enhertu for HER2-low metastatic breast cancer
References:
Cold S, et al. J Natl Cancer Inst. 2022;doi:10.1093/jnci/djac112.
Teglia F, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2617.
Yabroff KR, et al. J Natl Cancer Inst. 2022;doi:10.1093/jnci/djac044.
